Posterior amorphous corneal dystrophy
| Posterior amorphous corneal dystrophy | |
|---|---|
| Synonyms | PACD |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Corneal opacity, astigmatism, hyperopia |
| Complications | Corneal edema, glaucoma |
| Onset | Usually in childhood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Slit-lamp examination, genetic testing |
| Differential diagnosis | Other corneal dystrophies |
| Prevention | N/A |
| Treatment | Corrective lenses, corneal transplant |
| Medication | N/A |
| Prognosis | Generally stable, may require surgical intervention |
| Frequency | Rare |
| Deaths | N/A |
Posterior Amorphous Corneal Dystrophy (PACD) is a rare, non-progressive corneal dystrophy that affects the posterior layers of the cornea. It is characterized by the presence of amorphous, greyish opacities in the deeper layers of the cornea, which can lead to varying degrees of visual impairment. Unlike most corneal dystrophies that have a clear genetic basis, the exact etiology of PACD remains largely unknown, making it a subject of ongoing research.
Clinical Presentation
Patients with Posterior Amorphous Corneal Dystrophy typically present with bilateral, symmetric opacifications located in the posterior stroma, Descemet membrane, and endothelium. Despite these changes, the corneal surface remains smooth, and the epithelium is not involved. Most individuals with PACD are asymptomatic, with the dystrophy often discovered incidentally during routine eye examinations. However, in cases where the opacifications significantly affect the visual axis, patients may experience reduced visual acuity.
Diagnosis
The diagnosis of PACD is primarily clinical, based on the characteristic appearance of the cornea on slit-lamp examination. Advanced imaging techniques such as Optical Coherence Tomography (OCT) can provide detailed images of the corneal layers, helping to differentiate PACD from other posterior corneal dystrophies. Genetic testing is not typically useful in PACD due to its unclear genetic basis.
Management
Management of Posterior Amorphous Corneal Dystrophy is largely supportive. For individuals with significant visual impairment, corrective lenses or contact lenses may improve visual acuity. In severe cases where vision cannot be adequately corrected with glasses or contacts, corneal transplantation may be considered. However, given the non-progressive nature of PACD, surgical intervention is rarely required.
Epidemiology
PACD is a rare condition, with few documented cases in the medical literature. It can occur in individuals of any age and does not appear to have a predilection for any particular gender or ethnic group.
Pathophysiology
The pathophysiological mechanisms underlying PACD are not well understood. Histopathological studies have shown the presence of abnormal, amorphous material within the corneal stroma, Descemet membrane, and endothelium. This material stains positively with periodic acid-Schiff (PAS), suggesting a glycoprotein composition. The absence of inflammation and the non-progressive nature of the dystrophy suggest a developmental anomaly rather than a degenerative process.
Genetics
The genetic basis of Posterior Amorphous Corneal Dystrophy has not been clearly established. Unlike other corneal dystrophies that are often inherited in an autosomal dominant manner, PACD does not have a well-defined pattern of inheritance. Research into the genetic aspects of PACD is ongoing, with the hope of better understanding its etiology and potential genetic contributions.
Conclusion
Posterior Amorphous Corneal Dystrophy is a rare, non-progressive corneal disorder characterized by the presence of amorphous opacifications in the posterior cornea. While the condition is typically asymptomatic and discovered incidentally, it can cause visual impairment in some cases. The management of PACD is supportive, with surgical intervention rarely required. Ongoing research into the etiology and pathophysiology of PACD is essential for improving our understanding of this rare dystrophy.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD